Copenhagen’s SNIPR Biome Raises €35M In Series B Round

The funding includes support from new investors like the Cystic Fibrosis Foundation and Germany’s innovation agency SPRIN-D, along with existing backers such as Lundbeckfonden BioCapital, North-East Family Office, and Wellington Partners.

This comes about eight months after SNIPR Biome secured €20 million in venture debt from the European Investment Bank to fight antimicrobial resistance.

The funding will help advance a CRISPR-Cas therapy designed to target airway infections caused by Pseudomonas aeruginosa in people with cystic fibrosis (CF).

It will also support the development of a CRISPR-based approach to remove antibiotic resistance genes found in various bacteria within the human body.

Read Also - Sweden-based Flox Secures Nearly $1M In Seed Funding

In addition, the funds will aid the clinical progress of SNIPR001, the company’s CRISPR-based product for patients with blood cancers, including its ongoing Phase 1b trial.

Led by Christian Grøndahl, SNIPR Biome is a clinical-stage biotech company at the forefront of CRISPR-based medicine. The Danish company is developing innovative therapies that use CRISPR-Cas technology to precisely eliminate harmful bacteria or modify genes to treat and prevent disease.

SNIPR Biome was the first to administer an oral CRISPR therapeutic to humans and holds the first US and European patents for using CRISPR to target the microbiome.

Its lead product, SNIPR001, is currently in a Phase 1b clinical trial (NCT06938867) across eight cancer centers in the US, with support from CARB-X.

SNIPR’s groundbreaking technology is also being used in collaborations with major organizations, including CARB-X, the Gates Foundation, the Cystic Fibrosis Foundation, IPATH, SPRIN-D, and MD Anderson Cancer Center.

“This financing marks a pivotal milestone for SNIPR BIOME as we advance the clinical development of SNIPR001 for the prevention of bloodstream infections and continue to expand our infectious disease pipeline targeting pathogens of critical importance,” says Christian Grøndahl, Chief Executive Officer and Co-Founder of SNIPR BIOME, and he continued.

“This support shows the importance of addressing antimicrobial resistance and infectious disease and the unique position of SNIPR BIOME in the development landscape.”

About SNIPR Biome

Founded in 2011, SNIPR Biome develops CRISPR-based gene therapies targeting harmful bacteria in the microbiome. By enabling precision bacterial killing, the company aims to revolutionize treatment for hard-to-treat infections and microbiome-related diseases offering new hope for safe, effective therapies in areas with limited treatment options.